Back to EP Library
Core EP Topics

Atrial Fibrillation Ablation

From pulmonary-vein isolation to pulsed-field ablation — mechanism, patient selection, technique, and outcomes.

Atrial Fibrillation Catheter Ablation Rhythm Control
Updated: March 2026

1. Mechanism & Rationale

The landmark 1998 observation by Haissaguerre et al. demonstrated that the majority of atrial fibrillation (AF) is triggered by ectopic foci originating within the pulmonary veins (PVs). The myocardial sleeves extending into the PV ostia possess shorter refractory periods and serve as the substrate for rapid firing that initiates and perpetuates AF. This discovery established pulmonary vein isolation (PVI) as the cornerstone of catheter ablation for AF.

In paroxysmal AF, PV triggers are the dominant mechanism, and PVI alone is often sufficient. In persistent AF, the left atrium undergoes progressive electrical and structural remodeling — fibrosis, conduction slowing, and shortened refractoriness — creating a substrate capable of maintaining AF independent of triggers. Strategies targeting this substrate include ablation of complex fractionated atrial electrograms (CFAE), rotor mapping and ablation, and posterior wall isolation. However, incremental benefit of substrate modification beyond PVI remains debated.

Left atrial fibrosis is now recognized as a continuum. Late gadolinium enhancement (LGE) on cardiac MRI (the Utah staging system) correlates with ablation outcomes — patients with extensive fibrosis (Utah stage IV) have markedly lower success rates, raising questions about the utility of ablation in advanced remodeling.

Early rhythm control: The EAST-AFNET 4 trial demonstrated that early rhythm-control therapy (within 12 months of AF diagnosis) reduced the composite of cardiovascular death, stroke, and hospitalization compared with rate control. The EARLY-AF trial showed cryoballoon ablation as first-line therapy was superior to antiarrhythmic drugs (AADs) in preventing AF recurrence in patients with paroxysmal AF. Together with CABANA (ablation vs AAD, showing benefit in the as-treated analysis) and CASTLE-AF (ablation superiority in AF patients with heart failure and reduced EF), these trials have shifted the paradigm toward earlier and more aggressive rhythm control.

2. Patient Selection & Pre-Procedure

Guideline Indications

Current ACC/AHA/HRS guidelines assign a Class I recommendation for catheter ablation of symptomatic paroxysmal AF refractory to or intolerant of at least one Class I or Class III AAD. A Class IIa recommendation now supports ablation as first-line therapy for symptomatic paroxysmal AF, reflecting the growing evidence base from EARLY-AF, STOP-AF First, and CABANA.

AF Classification Matters

Paroxysmal AF (self-terminating within 7 days) carries the highest single-procedure success rates. Persistent AF (sustained >7 days or requiring cardioversion) and long-standing persistent AF (>12 months continuous) are associated with greater atrial remodeling and lower ablation success, often requiring more extensive lesion sets or staged procedures.

Left Atrial Size

An LA diameter >55 mm or an LA volume index >40 mL/m² is associated with higher recurrence rates. While markedly dilated atria are not an absolute contraindication, patient counseling should reflect the reduced likelihood of long-term freedom from AF.

Pre-procedural imaging: A transesophageal echocardiogram (TEE) or cardiac CT angiography is performed to exclude left atrial appendage (LAA) thrombus prior to ablation. CT also provides detailed PV anatomy (number, branching, common ostia) to guide procedural planning and 3D electroanatomic map integration.

Anticoagulation Management

The current standard of care is an uninterrupted DOAC strategy — continuing the direct oral anticoagulant through the procedure with the morning dose held on the day of ablation. This approach has been validated in the VENTURE-AF and RE-CIRCUIT trials, showing lower bleeding rates compared with uninterrupted warfarin while maintaining stroke protection. Heparin is administered intraprocedurally with an ACT target of 300–400 seconds after transseptal puncture.

Pre-procedural DCCV may be performed to restore sinus rhythm and assess baseline atrial electrical activity, particularly in persistent AF, aiding identification of PV reconnection gaps and non-PV triggers during the ablation procedure.

Pearl: In patients with persistent AF undergoing ablation, restoring sinus rhythm with DCCV at the beginning of the procedure allows voltage mapping in sinus rhythm, which can reveal low-voltage zones predictive of fibrosis and help guide substrate-based ablation strategies.

3. Ablation Techniques & Lesion Sets

Radiofrequency (RF) Ablation

Wide antral circumferential ablation (WACA) is the standard RF approach. Point-by-point lesions are delivered around the PV antrum, typically 1–2 cm from the ostium, to achieve electrical isolation of all four PVs (confirmed by entrance and exit block). Modern RF catheters incorporate contact force sensing (e.g., ThermoCool SmartTouch, TactiCath) — maintaining 5–40 g of force reduces the risk of both ineffective lesions (too little force) and perforation (excessive force).

The ablation index (AI) and Lesion Size Index (LSI) integrate contact force, power, and time into a single metric to predict lesion durability. The CLOSE protocol targets an AI of 400 on the posterior wall and 550 on the anterior wall with an interlesion distance ≤6 mm, yielding first-pass isolation rates >95% and 12-month freedom from AF >90% in paroxysmal AF.

Cryoballoon Ablation

The Arctic Front Advance (Medtronic) cryoballoon enables single-shot PVI by occluding the PV ostium and delivering circumferential cryothermal energy (target temperature −40 to −60 °C). The FIRE AND ICE trial (Kuck et al.) demonstrated non-inferiority of cryoballoon to RF ablation for paroxysmal AF with shorter procedure times and comparable safety. The cryoballoon is particularly efficient for PVI but less versatile for non-PV lesion sets.

Pulsed Field Ablation (PFA)

Pulsed field ablation represents a paradigm shift in ablation energy. PFA delivers high-voltage, ultrashort electrical pulses that cause irreversible electroporation of cardiomyocyte membranes. The key advantage is tissue selectivity — myocardial cells are preferentially ablated while the esophagus, phrenic nerve, and coronary arteries are largely spared. The Farapulse (Boston Scientific) system has demonstrated high acute PVI success rates with a significantly reduced risk of esophageal injury and phrenic nerve palsy compared with thermal ablation. The ADVENT trial confirmed non-inferiority of PFA to conventional thermal ablation for paroxysmal AF.

Additional lesion sets beyond PVI: In persistent AF, operators may add posterior wall isolation (box lesion), roof line, mitral isthmus line (connecting the mitral annulus to the left inferior PV), cavotricuspid isthmus (CTI) line (for typical atrial flutter), and SVC isolation (when SVC triggers are identified). The benefit of empiric substrate modification remains controversial — current evidence favors a PVI-first strategy with targeted additional lesions based on mapping findings.
Feature Radiofrequency (RF) Cryoballoon Pulsed Field (PFA)
Energy mechanism Resistive heating & conductive tissue necrosis Cryothermal injury (ice crystal formation) Irreversible electroporation
Lesion delivery Point-by-point Single-shot (balloon) Single-shot (multi-electrode catheter)
Tissue selectivity Low — thermal injury to adjacent structures Low — thermal injury to adjacent structures High — preferential myocardial effect
Esophageal fistula risk Present (rare but devastating) Present (rare) Minimal
Phrenic nerve injury Rare Notable risk (right PVs) Minimal
Lesion set flexibility Highly flexible — any chamber Limited to PVI Growing — PVI and beyond
Key trial CABANA, CLOSE protocol FIRE AND ICE ADVENT

4. Outcomes & Redo Procedures

Success Rates

Single-procedure freedom from atrial arrhythmia recurrence off AADs at 12 months is approximately 70–80% for paroxysmal AF and 50–70% for persistent AF. With repeat procedures, success rates for paroxysmal AF approach 85–90%. Long-standing persistent AF (>12 months) has the lowest success, with single-procedure rates around 40–50%.

PV Reconnection & Redo Ablation

Pulmonary vein reconnection is the most common cause of AF recurrence after initial ablation, identified in up to 80% of patients undergoing redo procedures. Reconnection occurs through gaps in the circumferential lesion set where tissue recovers electrical conduction. During redo ablation, high-density remapping identifies these gaps for targeted re-isolation.

Non-PV triggers become increasingly important in redo procedures and include the superior vena cava (SVC), coronary sinus (CS), posterior wall, left atrial appendage (LAA), crista terminalis, and ligament of Marshall. Provocative maneuvers with isoproterenol (up to 20 mcg/min) are used to unmask these triggers during the procedure.

Complications of AF ablation:
  • Cardiac tamponade (1–2%) — from catheter perforation or steam pops; requires emergent pericardiocentesis.
  • Stroke/TIA (<1%) — from thrombus or air embolism during transseptal access.
  • PV stenosis (<1% with antral ablation) — significantly reduced by ablating at the antrum rather than within the PV.
  • Atrioesophageal fistula (0.02–0.1%) — rare but often fatal; presents days to weeks post-ablation with fever, dysphagia, and neurological symptoms.
  • Phrenic nerve injury (2–5% with cryoballoon, rare with RF/PFA) — right phrenic nerve at risk during right-sided PV ablation; monitored with diaphragmatic compound motor action potential (CMAP) pacing.
  • Vascular access complications (1–2%) — groin hematoma, pseudoaneurysm, AV fistula.
Pearl: Atrioesophageal fistula, while exceedingly rare, is the most feared complication of AF ablation due to its high mortality (>50%). Any patient presenting with fever, chest pain, dysphagia, or neurological symptoms within 4 weeks of AF ablation should be evaluated urgently with CT (avoiding TEE, which can worsen the fistula by introducing air embolism).

5. Key References

  1. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666. doi:10.1056/NEJM199809033391003
  2. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure (CASTLE-AF). N Engl J Med. 2018;378(5):417-427. doi:10.1056/NEJMoa1707855
  3. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation (EAST-AFNET 4). N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422
  4. Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation (ADVENT). N Engl J Med. 2023;389(18):1660-1671. doi:10.1056/NEJMoa2307291
  5. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation (FIRE AND ICE). N Engl J Med. 2016;374(23):2235-2245. doi:10.1056/NEJMoa1602014